Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.50
-0.09 (-0.94%)
At close: Nov 21, 2024, 4:00 PM
9.55
+0.05 (0.53%)
After-hours: Nov 21, 2024, 6:16 PM EST
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 31, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 517 |
| CEO | Bradley Campbell |
Contact Details
Address: 47 Hulfish Street Princeton, New Jersey 08542 United States | |
| Phone | 609 662 2000 |
| Website | amicusrx.com |
Stock Details
| Ticker Symbol | FOLD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178879 |
| CUSIP Number | 03152W109 |
| ISIN Number | US03152W1099 |
| Employer ID | 20-0422823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley L. Campbell M.B.A. | Chief Executive Officer, President and Director |
| Simon Nicolas Reade Harford | Chief Financial Officer |
| David M. Clark | Chief People Officer |
| Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer |
| Samantha Prout | Chief Accounting Officer and Controller |
| Dr. Jill Weimer Ph.D. | Chief Science Officer |
| Andrew Faughnan | Senior Director of Investor Relations |
| Patrik S. Florencio Esq. | Global Chief Compliance and Risk Officer |
| Diana Moore | Head of Global Corporate Communications |
| Jayne C. Gershkowitz | Chief Patient Advocate |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 144 | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 144 | Filing |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |